RhyGaze
Private Company
Funding information not available
Overview
RhyGaze is a private, preclinical-stage biotechnology company pioneering optogenetic gene therapies for vision restoration. The company leverages a platform combining optogenetic proteins and gene therapy delivery tools, developed at IOB, to engineer photosensitivity into target cells within the retina. Led by a seasoned team with prior experience in the landmark gene therapy Luxturna, and backed by top-tier venture capital firms, RhyGaze aims to address a broad range of retinal diseases beyond single-gene disorders. The company operates from Basel, Switzerland, and Philadelphia, Pennsylvania.
Technology Platform
Optogenetic gene therapy platform combining engineered light-sensitive proteins (opsins) with targeted viral vectors (e.g., AAV) to confer photosensitivity to specific retinal cell types, enabling vision restoration independent of the underlying genetic cause of degeneration.
Opportunities
Risk Factors
Competitive Landscape
RhyGaze competes in the emerging optogenetic vision restoration space against companies like GenSight Biologics (GS030) and Nanoscope Therapeutics, which have already initiated clinical trials. It also faces indirect competition from mutation-specific gene therapies and retinal implant devices. Differentiation will hinge on superior visual outcomes, targeting strategy, and safety profile.